Skip to main content
    U

    UroGen Pharma Ltd (URGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.10
    +1.92 (+7.33%)

    Market Cap: $1.28B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    UroGen Pharma Ltd (URGN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to UroGen Pharma are Ultragenyx (RARE), Precigen (PGEN) and Uniqure NV (QURE). By market cap, UroGen Pharma ranks 8th of the 13 companies on this page; Aurinia Pharmaceuticals (AUPH) is the largest at $2.11B. The median P/E of the 4 companies with a P/E is 27.3x.

    Peer Comparison

    URGN's ROIC of -73.7% is below the peer median of -13.0%, and its revenue growth of 223.9% is above the median of 24.1%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    UroGen Pharma (URGN)$1.28BN/A5.7x-26.3%-73.7%223.9%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Precigen Inc (PGEN)$1.63B98.6x9.9x15.5%18.9%2438.0%0.00%
    Uniqure NV (QURE)$1.67BN/A75.8x0.0%-57.9%40.4%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Aurinia Pharmaceuticals Inc (AUPH)$2.11B15.2x6.4x97.7%N/A13.9%0.00%
    Geron Corporation (GERN)$622.98MN/A2.9x-22.0%-7.4%27.4%0.00%
    Tourmaline Bio Inc. (TRML)$1.23BN/AN/A0.0%N/A0.0%0.00%
    Pharming Group NV (PHAR)$891.80M39.3x2.4x6.3%7.9%20.8%0.00%
    Septerna, Inc. Common Stock (SEPN)$2.03BN/A20.3x-61.3%N/A-12.2%0.00%
    Neurogene Inc (NGNE)$495.37MN/AN/A0.0%-28.5%0.0%0.00%
    Prime Medicine, Inc. Common Stock (PRME)$949.85MN/A105.5x0.0%N/A243.9%0.00%
    Peer median$1.52B27.3x6.6x0.0%-13.0%24.1%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to UroGen Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Precigen Inc (PGEN)
    Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
    PGEN competitors
    Uniqure NV (QURE)
    uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases.
    QURE competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Aurinia Pharmaceuticals Inc (AUPH)
    Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China.
    AUPH competitors
    Geron Corporation (GERN)
    Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic...
    GERN competitors
    Tourmaline Bio Inc. (TRML)
    Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions...
    Pharming Group NV (PHAR)
    Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States...
    PHAR competitors
    Septerna, Inc. Common Stock (SEPN)
    Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform.
    SEPN competitors
    Neurogene Inc (NGNE)
    Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders...
    NGNE competitors
    Prime Medicine, Inc. Common Stock (PRME)
    Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology...
    PRME competitors

    Frequently Asked Questions About URGN

    Who are UroGen Pharma's main competitors?

    The companies most similar to UroGen Pharma include Ultragenyx (RARE), Precigen (PGEN), Uniqure NV (QURE), Nuvation Bio (NUVB) and Nurix Therapeutics (NRIX), listed from the closest match.

    Who is UroGen Pharma's biggest competitor?

    Aurinia Pharmaceuticals (AUPH) is the largest of the similar companies at $2.11B; Ultragenyx (RARE) is the closest match by business profile, size, sector and industry.

    How does URGN stock compare with its competitors?

    URGN's P/S is 5.7x against a peer median of 6.6x; its net margin is -26.3% against a peer median of 0.0%.

    Which of UroGen Pharma's competitors pays a higher dividend?

    UroGen Pharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is UroGen Pharma bigger than its competitors?

    No. UroGen Pharma is 8th by market cap among the 13 companies on this page; the largest is Aurinia Pharmaceuticals (AUPH) at $2.11B.